Results 161 to 170 of about 38,450 (306)

Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.

, 1991
Bispecific antibodies with specificity for the CD3/TCR complex of CTL and a target cell Ag can bridge both cell types and trigger cellular cytoxicity.
Brissinck, J, Demanet, Christian, Leo, Oberdan, Thielemans, Kris, Moser, Muriel   +4 more
core  

Junctional Adhesion Molecule‐A (JAM‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

European Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley, Roisin McAvera, Dimitri Bong, Lara Donnelly, Izabela Cymer, Marian Brennan, Joanna Fay, Lance Hudson, John Quinn, Siobhan V. Glavey, Ann M. Hopkins   +10 more
wiley   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, EarlyView.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source

T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. [PDF]

Front Immunol
Muthughavi K, Khokhar M, Jha HC, Pandey RK.   +3 more
europepmc   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Mawar Karsa, Ayu Karsa, Dayna Spurling, Lin Xiao, Emma Ronca, Angelika Bongers, Weiman Gao, Andrew J. Gifford, Ali El‐Ayoubi, Laurence C. Cheung, Rishi S. Kotecha, Richard B. Lock, Charis E. Teh, Guillaume Lessene, Murray D. Norris, Andrew Wei, Michelle Haber, Michelle J. Henderson, Donia M. Moujalled, Klaartje Somers   +19 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

JC Virus Reactivation Should Be Considered in Late Neurotoxicity Associated with Bispecific Antibody Therapy: A Comment. Comment on Bangolo et al. Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. <i>Cancers</i> 2025, <i>17</i>, 282. [PDF]

Cancers (Basel)
Iltar U, Atas U, Yucel OK, Salim O, Ündar L.   +4 more
europepmc   +1 more source

Preparation and characterization of beta(1)-bungarotoxin bispecific monoclonal antibody

, 2010
[[abstract]]A hybrid hybridoma (tetradoma) that produces bispecific monoclonal antibodies (mAbs)(2), which recognize two different epitopes on the A chain of beta(1)-bungarotoxin (beta(1)-bgt) at peptide sequences 46-51 and 100-106, has been obtained by ...
Yang CC;Chan HL
core  

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

British Journal of Haematology, EarlyView.
Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid   +2 more
wiley   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source